PT - JOURNAL ARTICLE AU - Zao Jiang AU - Gaojun Teng AU - Wen Fang AU - Xiaoyi Gu AU - Guozhao Li TI - Clinical Effects of Treatment for Lung Cancer with Double Points Cryoablation through Percutaneous Puncture Guided by Computed Tomography AID - 10.1007/s11805-009-0322-5 DP - 2009 Oct 01 TA - Clinical Oncology and Cancer Research PG - 322--327 VI - 6 IP - 5 4099 - http://www.cancerbiomed.org/content/6/5/322.short 4100 - http://www.cancerbiomed.org/content/6/5/322.full SO - Cancer Biol Med2009 Oct 01; 6 AB - OBJECTIVE To investigate the clinical effects of the application of double points cryoablation through percutaneous puncture for advanced lung cancer patients.METHODS Forty-one patients diagnosed with stage III-IV pulmonary carcinoma were selected for the study. The patients were found to have from 1 to 3 foci of carcinoma, and in each case the disease was limited to one lung. The study patients were divided randomly into 3 groups. There were 16 cases receiving routine chemotherapy and radiotherapy in group I, 13 cases treated with cryoablation at a single point in group II, and 12 cases treated with cryoablation at 2 points simultaneously in group III. The patients in the 2 cryoablation groups also received the same treatment as the patients did in group I. The clinical effects were evaluated within 6 months aft er treatment, and the survival rate was followed-up for 3 years.RESULTS The clinical effects were improved significantly aft er treatment in group II and in group III compared with those in group I (P < 0.05), including an enhanced regressive rate of 21%, postponed tumor progression of 50.58% and a clinical benefit rate of 92%. The effective rate of regression in group III was higher than that in group II, 43.59% (P < 0.05), and the 3-year survival rate was 37.25%. Significant differences in side effects were not found between the 2 cryoablation groups.CONCLUSION Cryosurgery ablation at 2 points, simultaneously, and directed at 1 foci might improve the effects of treatment and the prognosis of lung cancer patients, when used in combination with routine treatment.